ADAP
Price
$0.15
Change
+$0.02 (+15.38%)
Updated
Sep 26, 04:59 PM (EDT)
Capitalization
38.96M
39 days until earnings call
AKBA
Price
$2.74
Change
+$0.03 (+1.11%)
Updated
Sep 26, 04:59 PM (EDT)
Capitalization
726.5M
40 days until earnings call
Interact to see
Advertisement

ADAP vs AKBA

Header iconADAP vs AKBA Comparison
Open Charts ADAP vs AKBABanner chart's image
Adaptimmune Therapeutics
Price$0.15
Change+$0.02 (+15.38%)
Volume$172.89K
Capitalization38.96M
Akebia Therapeutics
Price$2.74
Change+$0.03 (+1.11%)
Volume$43.71K
Capitalization726.5M
ADAP vs AKBA Comparison Chart in %
Loading...
ADAP
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
AKBA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ADAP vs. AKBA commentary
Sep 27, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ADAP is a Buy and AKBA is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 27, 2025
Stock price -- (ADAP: $0.15 vs. AKBA: $2.74)
Brand notoriety: ADAP and AKBA are both not notable
ADAP represents the Biotechnology, while AKBA is part of the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: ADAP: 86% vs. AKBA: 50%
Market capitalization -- ADAP: $38.96M vs. AKBA: $726.5M
ADAP [@Biotechnology] is valued at $38.96M. AKBA’s [@Pharmaceuticals: Generic] market capitalization is $726.5M. The market cap for tickers in the [@Biotechnology] industry ranges from $98.9B to $0. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $63.66B to $0. The average market capitalization across the [@Biotechnology] industry is $1.9B. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $3.83B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ADAP’s FA Score shows that 0 FA rating(s) are green whileAKBA’s FA Score has 0 green FA rating(s).

  • ADAP’s FA Score: 0 green, 5 red.
  • AKBA’s FA Score: 0 green, 5 red.
According to our system of comparison, ADAP is a better buy in the long-term than AKBA.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ADAP’s TA Score shows that 4 TA indicator(s) are bullish while AKBA’s TA Score has 3 bullish TA indicator(s).

  • ADAP’s TA Score: 4 bullish, 5 bearish.
  • AKBA’s TA Score: 3 bullish, 4 bearish.
According to our system of comparison, both ADAP and AKBA are a bad buy in the short-term.

Price Growth

ADAP (@Biotechnology) experienced а +1.80% price change this week, while AKBA (@Pharmaceuticals: Generic) price change was -2.84% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.00%. For the same industry, the average monthly price growth was +9.18%, and the average quarterly price growth was +54.60%.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was -1.16%. For the same industry, the average monthly price growth was +24.25%, and the average quarterly price growth was +66.99%.

Reported Earning Dates

ADAP is expected to report earnings on Nov 05, 2025.

AKBA is expected to report earnings on Nov 06, 2025.

Industries' Descriptions

@Biotechnology (+4.00% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

@Pharmaceuticals: Generic (-1.16% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
AKBA($726M) has a higher market cap than ADAP($39M). AKBA YTD gains are higher at: 44.211 vs. ADAP (-72.174). AKBA has higher annual earnings (EBITDA): 11M vs. ADAP (-149.75M). AKBA has more cash in the bank: 137M vs. ADAP (26.1M). ADAP has less debt than AKBA: ADAP (48.7M) vs AKBA (53.4M). AKBA has higher revenues than ADAP: AKBA (204M) vs ADAP (65.1M).
ADAPAKBAADAP / AKBA
Capitalization39M726M5%
EBITDA-149.75M11M-1,361%
Gain YTD-72.17444.211-163%
P/E RatioN/AN/A-
Revenue65.1M204M32%
Total Cash26.1M137M19%
Total Debt48.7M53.4M91%
FUNDAMENTALS RATINGS
ADAP vs AKBA: Fundamental Ratings
ADAP
AKBA
OUTLOOK RATING
1..100
1558
VALUATION
overvalued / fair valued / undervalued
1..100
47
Fair valued
75
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
100100
PRICE GROWTH RATING
1..100
4147
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ADAP's Valuation (47) in the Biotechnology industry is in the same range as AKBA (75). This means that ADAP’s stock grew similarly to AKBA’s over the last 12 months.

ADAP's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as AKBA (100). This means that ADAP’s stock grew similarly to AKBA’s over the last 12 months.

ADAP's SMR Rating (100) in the Biotechnology industry is in the same range as AKBA (100). This means that ADAP’s stock grew similarly to AKBA’s over the last 12 months.

ADAP's Price Growth Rating (41) in the Biotechnology industry is in the same range as AKBA (47). This means that ADAP’s stock grew similarly to AKBA’s over the last 12 months.

ADAP's P/E Growth Rating (100) in the Biotechnology industry is in the same range as AKBA (100). This means that ADAP’s stock grew similarly to AKBA’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ADAPAKBA
RSI
ODDS (%)
Bearish Trend 2 days ago
90%
N/A
Stochastic
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
81%
Momentum
ODDS (%)
Bullish Trend 2 days ago
78%
Bearish Trend 2 days ago
85%
MACD
ODDS (%)
N/A
Bearish Trend 2 days ago
83%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
86%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
85%
Bearish Trend 2 days ago
85%
Advances
ODDS (%)
Bullish Trend 11 days ago
78%
Bullish Trend 29 days ago
86%
Declines
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
85%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
82%
Aroon
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
86%
View a ticker or compare two or three
Interact to see
Advertisement
ADAP
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
AKBA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
DNVYX29.16N/A
N/A
Davis NY Venture Y
RYPFX9.46N/A
N/A
Royce Small-Cap Fund Svc
TARKX33.09N/A
N/A
Tarkio
VSQAX18.33N/A
N/A
Invesco MSCI World SRI Index A
VTAIX11.17N/A
N/A
Virtus Tactical Allocation I

ADAP and

Correlation & Price change

A.I.dvisor indicates that over the last year, ADAP has been loosely correlated with NEVPF. These tickers have moved in lockstep 56% of the time. This A.I.-generated data suggests there is some statistical probability that if ADAP jumps, then NEVPF could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ADAP
1D Price
Change %
ADAP100%
+18.03%
NEVPF - ADAP
56%
Loosely correlated
N/A
AKBA - ADAP
41%
Loosely correlated
+1.11%
ETNB - ADAP
33%
Poorly correlated
N/A
CSLLY - ADAP
32%
Poorly correlated
N/A
PBM - ADAP
30%
Poorly correlated
+1.30%
More

AKBA and

Correlation & Price change

A.I.dvisor indicates that over the last year, AKBA has been loosely correlated with IPSC. These tickers have moved in lockstep 39% of the time. This A.I.-generated data suggests there is some statistical probability that if AKBA jumps, then IPSC could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To AKBA
1D Price
Change %
AKBA100%
+1.11%
IPSC - AKBA
39%
Loosely correlated
+4.41%
XERS - AKBA
39%
Loosely correlated
+4.33%
SYRE - AKBA
37%
Loosely correlated
+4.04%
KYMR - AKBA
36%
Loosely correlated
+4.75%
RXRX - AKBA
35%
Loosely correlated
+2.05%
More